Recombinant Human CDKN2C Protein，His

CDKN2C, also known as p18INK4c, is a crucial cyclin-dependent kinase inhibitor that plays a significant role in regulating the cell cycle, specifically by inhibiting the activity of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). Its primary function is to ensure that cells do not progress from the G1 phase to the S phase of the cell cycle, thereby preventing uncontrolled cell proliferation. Deregulation or mutation of CDKN2C has been implicated in various cancers, particularly in hematological malignancies and solid tumors, highlighting its potential as a tumor suppressor gene. Research on CDKN2C often focuses on understanding its structural properties, regulatory mechanisms, and how its dysfunction contributes to tumorigenesis. The pursuit of recombinant CDKN2C protein is vital for detailed biochemical studies and therapeutic application, as it enables researchers to elucidate its role in cell cycle regulation, investigate interactions with other cell cycle proteins, and explore potential avenues for cancer treatment. By producing and characterizing this recombinant protein, scientists can develop assays that may reveal novel insights into its function, paving the way for targeted therapies that could manipulate CDKN2C pathways in cancer cells. Moreover, understanding the molecular dynamics of CDKN2C can shed light on the development of resistance to existing therapies, making it a key focus in cancer research. Overall, CDKN2C represents a significant target for further investigation, with implications for improving cancer diagnosis, prognosis, and treatment strategies.